Global Urological Cancer Drugs Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|泌尿系統癌症治療藥的全球市場:2020年∼2027年 Global Urological Cancer Drugs Market - 2020-2027|
|出版日期: 2021年06月01日||內容資訊: 英文 180 Pages||
The global urological cancer drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Urological cancers affect the male and female urinary system's organs and structures and the male reproductive system. These cancers are fairly common. Types of urological cancers are: Bladder cancer affects the cells that line the urinary bladder, a small sac containing urine for excretion. Renal cancer forms in the tiny tubes that clean the blood of the kidneys. Renal pelvic cancer is a rare form of this disease that occurs in the kidney that connects to the bladder. Testicular cancer forms in testis and accounts for only one percent of all cancers in men. Urethral cancer occurs in the urethra, the tube that conducts urine from the bladder to the outside of the body. It is rare and occurs more often in men than in women. Symptoms don't occur until cancer has become more advanced. Blood in the urine (without pain) is a symptom of bladder, kidney and prostate cancer-at later stages, pelvic and back pain can also develop. Patients with prostate cancer may also have other changes in urination and sexual function. Those with testicular or penile cancer may notice a visible lesion on the skin, along with other skin changes or swelling. Any cancer patient can experience weight loss and fatigue. The market is expected to drive in the future due to the high prevalence rate of Urological cancers.
The global urological cancer drug market growth is driven by the growing incidence of urological cancers, and growing polices on reimbursement are among the key factors driving market growth.
Increasing incidence of urological cancers, is expected to drive the global urological cancer drug market during the forecast period.
As per the National Cancer Institute( NIH), in 2017, it was estimated 712,614 people were living with bladder cancer in the United States. In 2020, it was estimated that there would be 81,400 new cases of bladder cancer. In 2017, an estimated 3,170,339 men were living with prostate cancer in the United States. In 2020, it was estimated that there would be 191,930 new prostate cancer cases, and in 2017, an estimated 558,023 people were living with kidney and renal pelvis cancer in the United States. In 2020, it was estimated that there would be 73,750 new cases of kidney and renal pelvis cancer.
High treatment costs for chemotherapy and radiation therapy are likely to hinder the global leukapheresis market growth.
According to the study by the University of California and San Francisco, there is no standard cost of chemo. However, rough estimations can range from $10,000 to $200,000, and it was also estimated that $19,901 for robot-assisted prostatectomy to treat low-risk disease, to $50,276 for combined radiation therapy for high-risk disease.
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for Global Urological cancer drugs Market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.
Based on the product type, the global urological cancer drugs market is segmented into tablets and injections.
Tablets and Injections segment the global urological drugs market. The tablets segment accounts for the largest share in the urological drugs market. The drugs are classified into Xofigo (radium Ra 223 dichloride), Jevtana (cabazitaxel), Inlyta (axitinib), voterint (pazopanib), sutent (sunitinib malate), zytiga (abiraterone acetate), xtandi (enzalutamide), Provenge (sipuleucel-T).
Provenge is the first FDA-approved personalized immunotherapy that is clinically proven to extend life for certain men with advanced prostate cancer. Provenge® (sipuleucel-T) is a prescription drug used to treat certain men with advanced prostate cancer. Provenge is established cellular immunotherapy and is customized to each individual by using his immune cells.
Sutent is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC). In 2018, $1,049 million sales of Sutent occurred.
Xtandi slowed advanced prostate cancer progression. xtandi is FDA-approved to treat three forms of advanced prostate cancer. Men taking xtandi had a 71% lower chance of their cancer progressing than men not taking xtandi.
Zytiga® (abiraterone acetate) is a prescription drug that is used along with prednisone. zytiga® is used to treat men with prostate cancer that has spread to other parts of the body.
Votrient is a cancer drug that interferes with cancer cells' growth and spread in the body, and treats advanced renal cell carcinoma (kidney cancer).
Based on application, the global urological cancer drugs market is segmented into prostate cancer, bladder cancer, kidney cancer.
The prostate cancer segment is expected to drive for the largest share of global urological cancer drugs market. In 2017, the incidence data were available; in the United States, 1,701,315 new cancer cases were reported, and 599,099 people died of cancer. For every 100,000 people, 438 new cancer cases were reported.
In 2017, the incidence data were available; in the United States, 75,047 new Urinary Bladder cancer cases were reported, and 16,657 people died of this cancer. For every 100,000 people, 19 new Urinary Bladder cancer cases were reported.
In 2017, the incidence data were available; in the United States, 65,251 new Kidney and Renal pelvis cancer cases were reported, and 13,959 people died of this cancer. For every 100,000 people, 17 new Kidney and Renal pelvis cancer cases were reported.
Based on End-User, hospitals and surgical centers segment accounted for the largest market share
Due to the growing patient population, the hospitals and surgical centers segment held the largest market share in 2018. Although the rising number of diagnostic laboratories and imaging centers are likely to drive the industry in diagnostic laboratories & imaging centers.
North America served the largest share of the market due to the increasing prevalence of urological cancer diseases. According to the American Cancer Society, the urological cancer prevalence in 2019 estimated was 158,220 urinary system cancers and 174,650 prostate cancers. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and radiation therapy methods, the total availability of advanced diagnostic tools, and many companies are developing oncology products.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, as per the university of south Australia, In 2019, more than 19,500 prostate cancer cases were diagnosed in Australia. Globally, prostate cancer cases reached 1.28 million in 2018. These factors are driving the growth of the market in the forecast period.
The global urological cancer drugs market is quite competitive with some key competitors like Novartis, Pfizer, Roche Healthcare, AstraZeneca, Johnson & Johanson, Astellas, Celgene corporation, Bristol-Myers Squibb, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline Plc. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, According to clinicaltrials.gov;
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
Product- As part of Pfizer and Astellas' ongoing commitment to enzalutamide's clinical development, XTANDI is also evaluated in the EMBARK trial in men with high-risk non-metastatic Hormone-sensitive Prostate Cancer.
The global urological cancer drugs market report would provide an access to an approx. market data 61 tables, 52 figures and 240 pages.
LIST NOT EXHAUSTIVE